Shionogi's stroke drug fails mid-stage; Bayer's Hyrnuo gets expanded label
Plus news about Tevard Biosciences, Disc Medicine, InduPro, EMD Serono and Frazier Life Sciences. Shionogi fails mid-stage stroke trial: The company’s experimental drug redasemtide didn’t meet the primary endpoint in a ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- STAT+: FDA expands Bayer lung cancer drug approval statnews.com
